PD 0220245 - CAS 640736-79-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C24H26Cl2N4S2.2HCl
Molecular Weight:
578.45
COA:
Inquire
Targets:
Interleukin Related
Description:
PD 0220245 is a non-peptide interleukine 8 (IL-8) receptor antagonist.
Brife Description:
IL-8 receptor antagonist
Purity:
99%
Synonyms:
PD 0220245; PD0220245; PD-0220245; N-[6,7-dichloro-3-(5-thiophen-2-ylthiophen-2-yl)quinoxalin-2-yl]-N',N'-diethylbutane-1,4-diamine dihydrochloride
MSDS:
Inquire
InChIKey:
IBVKFSQIGWJQTN-UHFFFAOYSA-N
InChI:
InChI=1S/C24H26Cl2N4S2.2ClH/c1-3-30(4-2)12-6-5-11-27-24-23(22-10-9-21(32-22)20-8-7-13-31-20)28-18-14-16(25)17(26)15-19(18)29-24;;/h7-10,13-15H,3-6,11-12H2,1-2H3,(H,27,29);2*1H
Canonical SMILES:
CCN(CC)CCCCNC1=NC2=CC(=C(C=C2N=C1C3=CC=C(S3)C4=CC=CS4)Cl)Cl.Cl.Cl
1.Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor.
Li JJ;Carson KG;Trivedi BK;Yue WS;Ye Q;Glynn RA;Miller SR;Connor DT;Roth BD;Luly JR;Low JE;Heilig DJ;Yang W;Qin S;Hunt S Bioorg Med Chem. 2003 Aug 15;11(17):3777-90.
Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 receptor antagonists have been developed. The optimized derivatives, PD 0210293 (13y) and PD 0220245 (13r), show inhibition of both IL-8 receptor binding and IL-8-mediated neutrophil chemotaxis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Interleukin Related Products


CAS 240814-54-4 BMS-279700

BMS-279700
(CAS: 240814-54-4)

BMS-279700, belonging to a family of novel anilino 5-azaimidazoquinoxaline analogues, is an orally active lead candidate that blocks the production of proinflam...

Ustekinumab
(CAS: 815610-63-0)

Ustekinumab is a human monoclonal antibody approved for the treatment of psoriasis and Crohn's disease. Ustekinumab acts via blocking IL-12 and IL-23.

CAS 86727-00-6 CK 17

CK 17
(CAS: 86727-00-6)

CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation.

CAS 1252608-59-5 GIBH-130

GIBH-130
(CAS: 1252608-59-5)

GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses theIL-1βsecretion by activated microglia (IC50=3.4 nM). GIBH-13 const...

CAS 210825-31-3 CP 424174

CP 424174
(CAS: 210825-31-3)

CP 424174 has been found to be an inhibitor of stimulus-coupled IL-1β post-translational processing.

CAS 197917-10-5 CK-119

CK-119
(CAS: 197917-10-5)

CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly throug...

Secukinumab
(CAS: 875356-43-7)

Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis...

CAS 541550-19-0 Apilimod

Apilimod
(CAS: 541550-19-0)

Apilimod is a potent and orally bioavailable inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain au...

Chemical Structure

CAS 640736-79-4 PD 0220245

Quick Inquiry

Verification code

Featured Items